Indeed, an increased enrichment of mutated IFNγ signaling related genes such as interferon gamma receptor 1 and 2, Janus kinase 2, and interferon regulatory factor 1 was observed in non-responders to ipilimumab (anti-CTLA-4 mAb) recapitulating the loss of IFNγ signaling-related genes in cancer cells is a mechanism of resistance to anti-CTLA-4 therapy [38]. The gene discussed is CTLA4; the disease is cancer.